Eli Lilly and Company (LLY)
Eli Lilly and Company reported revenue of $65.18B for the fiscal year ended Dec 31, 2025, up 44.7% from $45.04B the year before. Net income was $20.64B, a net margin of 31.7% (prior year: $10.59B). At the end of that fiscal year the company reported total assets of $112.48B and shareholders' equity of $26.54B.
Revenue
$65.18B
+44.7% vs prior year
Net income
$20.64B
Net margin 31.7%
Diluted EPS
$22.95
USD per share
Total assets
$112.48B
At Dec 31, 2025
Equity
$26.54B
At Dec 31, 2025
Shares outstanding
941M
As of Oct 26, 2026
Explore Eli Lilly and Company's filings
- Revenue by year — annual and quarterly revenue with growth rates
- Income statement & cash flow — profit, margins, EPS and operating cash flow
- Balance sheet — assets, liabilities, equity, cash and debt
- SEC filings — 10-K and 10-Q filings with links to EDGAR
Latest SEC filings
- 10-QFiled Oct 29, 2026
- 10-QFiled Aug 5, 2026
- 10-QFiled Apr 30, 2026
- 10-KFiled Feb 12, 2026
- 10-QFiled Oct 30, 2025
- 10-QFiled Aug 7, 2025
Compare Eli Lilly and Company
- MRKLLY vs MRK
Source: SEC EDGAR XBRL company facts for CIK 59478 (raw data). Most recent filing in this dataset: 10-Q filed Oct 29, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.